Differential impact of proton pump inhibitor on survival outcomes of patients with advanced urothelial carcinoma treated with chemotherapy versus pembrolizumab.

Ikko Tomisaki Mirii HaradaShigeru SakanoMichikazu TeradoRyoichi HamasunaShuji HaradaHiroomi MatsumotoSoichiro AkasakaYujiro NagataAkinori MinatoKen-Ichi HaradaNaohiro Fujimoto

Published in: International journal of urology : official journal of the Japanese Urological Association (2023)

The use of a concomitant proton pump inhibitor use had no impact on oncological outcomes in patients with advanced urothelial carcinoma treated with paclitaxel-gemcitabine therapy, different from those treated with pembrolizumab.

Keyphrases

squamous cell carcinoma
prostate cancer
radiation therapy
insulin resistance
bone marrow
electron transfer
smoking cessation
glycemic control